Effect of Inhaled Albuterol in Pulmonary Hypertension

Completed · Phase 2 · Has a placebo group

Conditions studied: Pulmonary Hypertension

In brief

The purpose of the present pilot study is to test the hypothesis that in patients with group 1 pulmonary arterial hypertension (PAH) who are on regular oral pulmonary vasodilator therapy, inhaled albuterol causes transient pulmonary vasodilation.

Key facts

Study ID

NCT03270332

Run by

University of Miami

People needed

10

Starts

2017-10-05

Expected to finish

2020-07-02

Last updated by the study team

2021-08-30

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• A Mean Pulmonary Artery Pressure >25mmHg, Pulmonary Vascular Resistance >3 wood/units and pulmonary arterial wedge pressure <15mmHg, as documented by right heart catheterization within the last 3 years
• Regular use of oral pulmonary vasodilators

You may not qualify if…

• Presence of chronic respiratory disease (as documented by prior lung imaging and pulmonary function tests), cardiovascular disease (as documented by prior echocardiography and/or left heart catheterization), thromboembolic PAH (as documented by pulmonary angiography)
• women of childbearing potential who do not use accepted birth- control measures
• pregnant and breast-feeding women
• respiratory infection within 4 weeks of testing
• A systemic systolic arterial BP> 150 and/or diastolic arterial BP>100 on the experiment day
• A resting O2 saturation of < 90%
• Current smoking
• BMI >35 kg/m2 and/or a diagnosis of obstructive sleep apnea
• Use of inhaled or intravenous pulmonary vasodilators

Where it is running

• University of Miami — Miami, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.